Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Abstract Text:

OBJECTIVE: This study was undertaken to assess the impact of 17 alpha hydroxyprogesterone caproate treatment on future medical costs for expectant mothers with a prior spontaneous preterm birth. STUDY DESIGN: Data on the costs of preterm birth were combined with published data on the effectiveness of 17 alpha hydroxyprogesterone caproate to produce estimates of the effect of treatment on expected future direct medical costs. These estimates were compared with an estimate of the cost of a typical 17 alpha hydroxyprogesterone caproate treatment regimen to estimate the net savings per treated woman. RESULTS: Treatment is estimated to reduce initial neonatal hospitalization costs by 3800 dollars per woman treated with 17 alpha hydroxyprogesterone caproate. Expected lifetime medical costs (discounted) of treated infants are estimated to decline 15,900 dollars. CONCLUSIONS: Treating expectant mothers with a prior spontaneous preterm birth with 17 alpha hydroxyprogesterone caproate generates future medical cost savings that substantially exceed the cost of treatment. If this population were universally treated with 17 alpha hydroxyprogesterone caproate, discounted lifetime medical costs of their offspring could be reduced by more than 2.0 billion dollars annually.

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Publishing Authors By Initials

For similar female urogenital diseases and pregnancy complications: pregnancy complications: obstetric labor complications: obstetric labor, premature: premature birth research abstracts see: female urogenital diseases and pregnancy complications: pregnancy complications: obstetric labor complications: obstetric labor, premature: premature birth research

PUBMED ID PMID:

MEDLINE DATE:

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Journal Published:

PUBLICATION TYPE: Review

Journal: American journal of obstetrics and gynecology

VOLUME: 196

Page Numbers: 219.e1-7

Journal Abbreviation: Am. J. Obstet. Gynecol.

ISSN: 1097-6868

DAY: 3

MONTH: Mar

YEAR: 2007

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Information

Number of References: 26

LANGUAGE: eng

NlmUniqueID: 370476

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Keywords Mesh Terms:

KEYWORDS: Premature Birth

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Information

Substance Name: 17-alpha-hydroxy-progesterone caproate

Registry Number: 630-56-8

Grant and Affiliation Information for Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.

AFFILIATION: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH, USA.

Country: United States

AGENCY: United States NICHD

GRANT: K12 HD98004

ACRONYM: HD

MEDLINETA: Am J Obstet Gynecol

REFSOURCE: Am J Obstet Gynecol. 2007 Mar;196(3):194

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate Related Publications

• A missense mutation in the murine Opa3 gene models human Costeff syndrome.
• An "overtrained" ophthalmologist responds.
• Experience with evaluation of knowledge in technical disciplines.
• Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 2: Hypercholesterolemia.
• Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 3: Hypertriacylglycerolemia.
• Hyperlipidemia, dyslipoproteinemia and apolipoproteinopathia--classification and risk of atherosclerosis. Part 4: Apolipoproteinopathia.
• Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
• Pyrimidine acyclic nucleoside phosphonates and phosphorylated analogs (part 2): syntheses and investigation of their inhibitory effects towards human thymidine phosphorylase.
• Systems analysis of the culture physiology in acetone-butanol fermentation.
• Thymoxamine in the treatment of traumatic mydriasis.